Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients.

Eugenia Vispo, Muge Cevik, Juergen K Rockstroh, Pablo Barreiro, Mark Nelson, Andrew Scourfield, Christoph Boesecke, Jan-Christian Wasmuth, Vincent Soriano, European Network of Clinical Trials (NEAT)

Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013 Apr

filter terms:

Noncirrhotic portal hypertension (NCPH) is a rare but potentially life-threatening complication in patients with human immunodeficiency virus (HIV). Cases of NCPH have been reported in HIV-negative individuals as result of treatment with thiopurines for leukemia or inflammatory bowel disease. Exposure to didanosine, which is also a purine analogue, predisposes to NCPH in the HIV setting. However, it is unclear why NCPH only develops in a small subset of didanosine-treated patients. A multicenter, case-control study was conducted to investigate the role of pharmacogenomics in NCPH in HIV patients with prior didanosine exposure. Three controls were chosen for each case, adjusted for sex, age, CD4 counts, plasma HIV-RNA, and site. Tagging 36 single-nucleotide polymorphisms (SNPs) at enzymes involved in the purine metabolism (inosine triphosphatase, 5'-nucleotidase cytosolic-II, purine nucleoside phosphorylase and xanthine oxidase) was performed using SNPlex microarray technology. Eighty individuals were examined; 22 with NCPH and 58 matched controls. Two SNPs at the 5'-nucleotidase gene were associated with NCPH: rs11191561 (48% CG/GG vs 17% CC; P=.003) and rs11598702 (40% CC/CT vs 9% TT; P=.003). SNPs at another 2 loci at the xanthine oxidase gene were also associated with NCPH: rs1429376 (71% AA vs 23% CC/AC; P=.015) and rs1594160 (71% AA vs 23% CC/AC; P=.015). There was a cumulative risk of NCPH for these 4 SNPs: 7%, 26%, 42%, 50%, and 100%, respectively, for 0, 1, 2, 3, or all SNPs (P=.001). SNPs at the 5'-nucleotidase and xanthine oxidase genes influence the risk of NCPH in HIV patients treated with didanosine.

Citation

Eugenia Vispo, Muge Cevik, Juergen K Rockstroh, Pablo Barreiro, Mark Nelson, Andrew Scourfield, Christoph Boesecke, Jan-Christian Wasmuth, Vincent Soriano, European Network of Clinical Trials (NEAT). Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013 Apr;56(8):1117-22